Proteomic Landscapes of 3D and 2D Models of High-Grade Serous Ovarian Carcinoma: Implications for Carboplatin Response

Udai Banerji(Royal Marsden NHS Foundation Trust)

Journal of Proteome Research

August 27, 2025

10.1021/acs.jproteome.5c00391

Cited by 1

Related Papers

First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

|Clinical Cancer Research|2014|47

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

|PLoS ONE|2017|16

Characterizing functional DNA damage and response caused by the combination of CHK1 and WEE1 inhibitors in ovarian and breast cancer models

|BJC Reports|2024|3

Supplementary Data from The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

|Unknown|2023|0

Supplementary Data from The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

|Unknown|2023|0